The Role of Synbiotics in Alleviating Fatigue Among Multiple Sclerosis Patients: A Randomized Controlled Trial
Abstract
Background: Multiple sclerosis (MS) is a chronic, inflammatory neurological condition characterized by debilitating symptoms, including fatigue, which significantly impacts patients’ quality of life. Probiotics are emerging as a potential intervention to alleviate MS-related fatigue through immunomodulatory and gut–brain axis effects. Objective: This study aimed to evaluate the efficacy of Familact, Multistrains probiotics, and a prebiotic, in reducing fatigue among MS patients compared to a placebo. Methods: A double-blind, randomized controlled trial was conducted with 54 MS patients allocated to receive either Familact or a placebo for 30 days. Fatigue levels were assessed using the Fatigue Severity Scale at baseline and after the intervention. Statistical analyses included appropriate comparative tests. Results: Patients receiving Familact showed significant improvements in fatigue levels compared to the placebo group, with no reported adverse reactions. Conclusions: Familact suggests the potential to reduce MS-related fatigue. Further large-scale, long-term studies are warranted to confirm these findings and explore underlying mechanisms.
Related
- Disease-modifying therapies (DMTs) discontinuation in older relapsing-remitting multiple sclerosis (RRMS) patients with stable disease: Two-year randomized, controlled trial.
- Effects of Occupational Therapy Interventions on Occupational Performance and Physical and Cognitive Fatigue in Adults with Multiple Sclerosis: A Systematic Review of Randomized Controlled Trials
- Efficacy of sacral neuromodulation versus placebo in patients with multiple sclerosis with neurogenic lower urinary tract, bowel, and sexual dysfunction: study protocol for a multicenter randomized placebo-controlled trial
- Impact of the Family‐Centered Empowerment Model on Health‐Promoting Lifestyle and Psychological Well‐Being in Patients With Multiple Sclerosis: A Randomized Controlled Clinical Trial
- Movement Intensity in the Minutes Before a Fall: A Lag-Controlled, Activity-Matched Time-Stratified Case-Crossover Analysis of Home Monitoring in Multiple Sclerosis
BibTeX
@article{jadidi2026role,
title = {{The Role of Synbiotics in Alleviating Fatigue Among Multiple Sclerosis Patients: A Randomized Controlled Trial}},
author = {Ali Jadidi and Bahareh Ranjbari and Alireza Rezaei Ashtiani and Mehdi Safarabadi},
journal = {International Journal of Preventive Medicine},
year = {2026},
month = sep,
doi = {10.4103/ijpvm.ijpvm_130_25},
url = {https://doi.org/10.4103/ijpvm.ijpvm_130_25},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - The Role of Synbiotics in Alleviating Fatigue Among Multiple Sclerosis Patients: A Randomized Controlled Trial
AU - Ali Jadidi
AU - Bahareh Ranjbari
AU - Alireza Rezaei Ashtiani
AU - Mehdi Safarabadi
PY - 2026
DA - 2026/09/01
JO - International Journal of Preventive Medicine
DO - 10.4103/ijpvm.ijpvm_130_25
UR - https://doi.org/10.4103/ijpvm.ijpvm_130_25
AB - Background: Multiple sclerosis (MS) is a chronic, inflammatory neurological condition characterized by debilitating symptoms, including fatigue, which significantly impacts patients’ quality of life. Probiotics are emerging as a potential intervention to alleviate MS-related fatigue through immunomodulatory and gut–brain axis effects. Objective: This study aimed to evaluate the efficacy of Familact, Multistrains probiotics, and a prebiotic, in reducing fatigue among MS patients compared to a placebo. Methods: A double-blind, randomized controlled trial was conducted with 54 MS patients allocated to receive either Familact or a placebo for 30 days. Fatigue levels were assessed using the Fatigue Severity Scale at baseline and after the intervention. Statistical analyses included appropriate comparative tests. Results: Patients receiving Familact showed significant improvements in fatigue levels compared to the placebo group, with no reported adverse reactions. Conclusions: Familact suggests the potential to reduce MS-related fatigue. Further large-scale, long-term studies are warranted to confirm these findings and explore underlying mechanisms.
SN - 2008-7802
SN - 2008-8213
ER -